Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

被引：0
|
作者：
Jung Won Chun
Sang Hyub Lee
Joo Seong Kim
Namyoung Park
Gunn Huh
In Rae Cho
Woo Hyun Paik
Ji Kon Ryu
Yong-Tae Kim
机构：
[1] Center for Liver and Pancreatobiliary Cancer,Department of Internal Medicine and Liver Research Institute
[2] Research Institute and Hospital,undefined
[3] National Cancer Center,undefined
[4] Seoul National University Hospital,undefined
[5] Seoul National University College of Medicine,undefined
来源：
BMC Cancer | / 21卷
关键词：
Pancreatic neoplasms; Folfirinox; Albumin-bound paclitaxel; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival
    Pacheco-Barcia, V.
    France, T.
    Zogopoulos, G.
    Bouganim, N.
    Donnay, O.
    Alcindor, T.
    Mondejar Solis, R.
    Guo, K.
    Martin, E.
    Colomer, R.
    Asselah, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [33] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Wang, Ying
    Camateros, Pierre
    Cheung, Winson Y.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (01) : 62 - 68
  • [34] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Ying Wang
    Pierre Camateros
    Winson Y. Cheung
    Journal of Gastrointestinal Cancer, 2019, 50 : 62 - 68
  • [35] Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
    Maeda, O.
    Yokoyama, Y.
    Yamaguchi, J.
    Ota, A.
    Matsuoka, A.
    Morita, S.
    Inoue, M.
    Mizutani, T.
    Shimokata, T.
    Urakawa, H.
    Mitsuma, A.
    Nagino, M.
    Ando, Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 69 - 69
  • [36] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [37] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [38] Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 345 - 352
  • [39] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
    Riedl, J. M.
    Posch, F.
    Horvath, L.
    Gantschnigg, A.
    Renneberg, F.
    Schwarzenbacher, E.
    Moik, F.
    Barth, D.
    Stotz, M.
    Schaberl-Moser, R.
    Pichler, M.
    Stoeger, H.
    Greil, R.
    Djanani, A.
    Schlick, K.
    Gerger, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S942 - S942
12345